Innate Pharma (XPAR:IPH) Other Net Income (Loss) : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Other Net Income (Loss)?

Innate Pharma's Other Net Income (Loss) for the six months ended in Dec. 2023 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Innate Pharma's quarterly Other Net Income (Loss) increased from Dec. 2022 (€-0.06 Mil) to Jun. 2023 (€0.00 Mil) but then stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Innate Pharma's annual Other Net Income (Loss) increased from Dec. 2021 (€-7.33 Mil) to Dec. 2022 (€-0.13 Mil) and increased from Dec. 2022 (€-0.13 Mil) to Dec. 2023 (€0.00 Mil).

Innate Pharma Other Net Income (Loss) Historical Data

The historical data trend for Innate Pharma's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Other Net Income (Loss) Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

-28.63

-63.16

-7.33

-0.13

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-1.08	-0.07	-0.06	-	-

Innate Pharma Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Innate Pharma Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines